Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

被引：2
|
作者：
Jindy, Tanya
Jiang, Cindy Y.
Alhalabi, Omar
Nguyen, Charles B.
Nizam, Amanda
Basu, Arnab
Bilen, Mehmet Asim
Zakharia, Yousef
Milowsky, Matthew I.
Brown, Jason R.
Kilari, Deepak
Emamekhoo, Hamid
Hoimes, Christopher J.
Khaki, Ali Raza
Gupta, Shilpa
Grivas, Petros
Bellmunt, Joaquim
Campbell, Matthew T.
Alva, Ajjai Shivaram
Koshkin, Vadim S.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Hematol Oncol Fellowship, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
[4] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[5] Cleveland Clin, Cleveland, OH USA
[6] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA
[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Med Coll Wisconsin, Dept Med, Div Hematol Oncol, Milwaukee, WI USA
[12] Univ Wisconsin, Madison, WI USA
[13] Duke Univ, Duke Canc Inst, Durham, NC USA
[14] Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA USA
[15] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[16] Univ Washington, Div Hematol & Oncol, Seattle, WA USA
[17] Fred Hutchinson Canc Ctr, Seattle, WA USA
[18] Dana Farber Canc Inst, Boston, MA USA
[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA
[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-12099; 261-492-3532-2370-7650-2700; 261-566-9263; 4; 2; 3224; 3; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / 652
页数：1
相关论文
共 50 条
  • [41] Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer
    Koshkin, V. S.
    Sun, Y.
    Osterman, C. K.
    Natesan, D.
    Su, C.
    Lemke, E.
    Khaki, A. R.
    Johnson, A.
    Owens, X.
    Park, J. J.
    Basu, A.
    Barata, P. M. Coelho
    Davis, N.
    Grivas, P.
    Milowsky, M.
    Kilari, D.
    Alva, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S594 - S594
  • [42] Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study
    Shindo, Tetsuya
    Hashimoto, Kohei
    Kenuka, Toshiki
    Miyamoto, Shintaro
    Hiyama, Yoshiki
    Fukuta, Fumimasa
    Kunishima, Yasuharu
    Okada, Manabu
    Matsukawa, Masanori
    Kato, Ryuichi
    Senda, Masaya
    Wanifuchi, Atsushi
    Sato, Shunsuke
    Kobayashi, Ko
    Tanaka, Toshiaki
    Masumori, Naoya
    JOURNAL OF GERIATRIC ONCOLOGY, 2025, 16 (02)
  • [43] Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma
    Hara, Takuto
    Suzuki, Kotaro
    Tobe, Taisuke
    Ueki, Hideto
    Wakita, Naoto
    Okamura, Yasuyoshi
    Bando, Yukari
    Terakawa, Tomoaki
    Hyodo, Yoji
    Chiba, Koji
    Teishima, Jun
    Yao, Akihisa
    Miyake, Hideaki
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025,
  • [44] Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
    Koshkin, Vadim S.
    Henderson, Nicholas
    Kilari, Deepak
    Jindal, Tanya
    Alhalabi, Omar
    Freeman, Dory
    Basu, Arnab
    Barata, Pedro C.
    Bilen, Mehmet Asim
    Zakharia, Yousef
    Emamekhoo, Hamid
    Shah, Sumit
    Milowsky, Matthew I.
    Davis, Nancy B.
    Gupta, Shilpa
    Hoimes, Christopher J.
    Grivas, Petros
    Bellmunt, Joaquim
    Campbell, Matthew T.
    Alva, Ajjai Shivaram
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [45] Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis
    Taguchi, Satoru
    Kawai, Taketo
    Ambe, Yoshiki
    Kishitani, Kenjiro
    Noda, Michio
    Kaneko, Tomoyuki
    Miyakawa, Jimpei
    Nakamura, Yu
    Hoshina, Hayato
    Obinata, Daisuke
    Yamaguchi, Kenya
    Kakutani, Shigenori
    Furuya, Yoshitsune
    Sato, Yujiro
    Adachi, Yume
    Sugimoto, Kazuma
    Sato, Keigo
    Tabata, Mariko
    Tanaka, Takehiro
    Nara, Katsuhiko
    Uemura, Yukari
    Kamei, Jun
    Akiyama, Yoshiyuki
    Sato, Yusuke
    Yamada, Yuta
    Niimi, Aya
    Yamada, Daisuke
    Takada, Tappei
    Takahashi, Sayuri
    Yamada, Yukio
    Miyazaki, Hideyo
    Enomoto, Yutaka
    Nishimatsu, Hiroaki
    Fujimura, Tetsuya
    Fukuhara, Hiroshi
    Nakagawa, Tohru
    Takahashi, Satoru
    Kume, Haruki
    INTERNATIONAL JOURNAL OF UROLOGY, 2025, 32 (03) : 270 - 276
  • [46] The role of organ-specific response to enfortumab vedotin on survival in advanced urothelial carcinoma patients: A Japanese multicenter retrospective study
    Hayakawa, N.
    Kaneko, G.
    Ikarashi, D.
    Endo, Y.
    Sakura, Y.
    Yamashita, R.
    Obara, W.
    Kondo, Y.
    Kikuchi, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S1516 - S1516
  • [47] Characterization of Polyneuropathy in Patients Receiving Enfortumab Vedotin for the Treatment of Metastatic Urothelial Carcinoma
    Badii, Melody
    Mar, Nataliya
    Habib, Ali
    NEUROLOGY, 2023, 100 (17)
  • [48] Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma
    Brown, Jacqueline T.
    Nazha, Bassel
    Liu, Yuan
    Lozada, Kelsea
    Smith, Jeremy D.
    Hartman, Caitlin
    McClintock, Greta Russler
    Kucuk, Omer
    Carthon, Bradley Curtis
    Harvey, R. Donald
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] EVALUATION OF QTC INTERVAL IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA FOLLOWING ENFORTUMAB VEDOTIN ADMINISTRATION.
    Yamada, A.
    Fukushi, R.
    Kadokura, T.
    Garg, A.
    Tang, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S58 - S58
  • [50] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
    Li, Siming
    Shi, Yanxia
    Dong, Haiying
    Guo, Hongqian
    Xie, Yu
    Sun, Zhongquan
    Zhang, Xiaoping
    Kim, Eric
    Zhang, Jun
    Li, Yue
    Xu, Chenming
    Kadeerbai, Haishan
    Lee, Sue
    Gorla, Seema
    Guo, Jun
    Sheng, Xinan
    CANCER MEDICINE, 2024, 13 (21):
12345